Clinical trials: Risk of Venous Thrombosis
- Condition Risk of Venous Thrombosis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Antithrombin Deficiency, Congenital
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures.
- Trial name
- rhAT (NCT00056550)
- Testing
- Recombinant Human Antithrombin (rhAT)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 14 people
- Sponsor
- rEVO Biologics
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Pulmonary Embolism, Deep Vein Thrombosis
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01403090
- Testing
- Angel Catheter
- Where
- 2 sites in Colombia
- Volunteers
- 8 people
- Sponsor
- BiO2 Medical
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim